Luitpold Pharmaceuticals, Inc. Invests in BioMimetic Therapeutics, Inc.

We advised BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) in the sale of its orofacial therapeutic business, including its bone and tissue regeneration treatment, GEM 21S and related intellectual property, to Luitpold Pharmaceuticals, Inc., a division of Daiichi Sankyo Co. Ltd of Japan. Under the agreement Luitpold has agreed to pay BioMimetic approximately $45 million in cash, in addition to royalty payments based on sales of existing and future products in the dental and orofacial therapeutic fields. 

The sale allows BioMimetic to refocus its business on the development and commercialization of its orthopedic and sports medicine products, GEM OS1 and GEM OS2.

This experience gained prior to joining Bass, Berry & Sims PLC.

You Also May Be Interested In:

  • We advise a multinational specialty manufacturing and technology company in all domestic and international privacy and data protection matters, including assistance in implementing a privacy compliance program and drafting license and services agreements, including data use and rights terms, and data access and deletion request response procedures.

    We advise a multinational specialty manufacturing and technology company in all domestic and international privacy and data protection matters, including...
    Client Type: Private Company
  • We advise a leading U.S. provider of senior care and assisted living communities with respect to state privacy law, PCI...
    Client Type: Public Company
  • We serve as lead outside counsel for a global Fortune 500 media company negotiating data protection and privacy agreements and contractual terms, including for engagements of ad tech, security infrastructure, financial services, and clinical healthcare service providers, as well as advising on U.S. and international security and privacy regulations and self-regulatory framework compliance.

    We serve as lead outside counsel for a global Fortune 500 media company negotiating data protection and privacy agreements and...
    Client Type: Public Company